Short Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Rises By 8.7%

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 31st total of 5,060,000 shares. Based on an average trading volume of 2,120,000 shares, the days-to-cover ratio is presently 2.6 days.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. raised its stake in shares of Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the period. Fullcircle Wealth LLC purchased a new position in shares of Adaptimmune Therapeutics during the third quarter worth about $33,000. GSA Capital Partners LLP purchased a new stake in Adaptimmune Therapeutics in the third quarter valued at approximately $95,000. Baillie Gifford & Co. increased its holdings in shares of Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after buying an additional 1,626,657 shares during the last quarter. Finally, FMR LLC grew its position in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after acquiring an additional 50,419 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Price Performance

ADAP opened at $0.59 on Tuesday. The company has a market capitalization of $150.46 million, a price-to-earnings ratio of -2.67 and a beta of 2.42. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average price of $0.62 and a 200-day moving average price of $0.85. Adaptimmune Therapeutics has a twelve month low of $0.53 and a twelve month high of $2.05.

Analyst Ratings Changes

Several analysts have recently commented on the stock. StockNews.com downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. HC Wainwright dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Mizuho cut their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Finally, Guggenheim decreased their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $2.79.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.